Nurix Therapeutics, Inc. Common stock
NRIXNurix Therapeutics, Inc. is a biotechnology company focused on developing innovative small molecule therapies that modulate the ubiquitin-proteasome system to treat cancer, autoimmune, and inflammatory diseases. The company's approach involves targeting protein degradation pathways to selectively manipulate cellular processes and restore healthy function. Founded to advance precision medicine, Nurix leverages its expertise in drug discovery to develop targeted therapeutics with potential for broad clinical applications.
Company News
The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep...
Nurix Therapeutics reported promising Phase 1 trial results for bexobrutideg, an investigational drug for relapsed or refractory chronic lymphocytic leukemia, showing an 83% objective response rate and a median progression-free survival of 22.1 months.
Nurix Therapeutics will host a webcast on December 8, 2025, to present new clinical data on bexobrutideg (NX-5948), an investigational BTK degrader for treating chronic lymphocytic leukemia and Waldenström macroglobulinemia.
Nurix Therapeutics will present updated clinical data on bexobrutideg, a novel BTK degrader, at the ASH Annual Meeting, showcasing results in chronic lymphocytic leukemia and Waldenström macroglobulinemia treatments.
Nurix Therapeutics raised $250 million through a stock offering to fund clinical development of drug candidates targeting chronic lymphocytic leukemia and potential autoimmune indications.
